Lv11
70 积分 2023-04-09 加入
Safety and efficacy of the anti-TL1A monoclonal antibody tulisokibart for Crohn's disease: a phase 2a induction trial
15分钟前
待确认
Anti-TL1A antibody, afimkibart, in moderately-to-severely active ulcerative colitis (TUSCANY-2): a multicentre, double-blind, treat-through, multi-dose, randomised, placebo-controlled, phase 2b trial
18分钟前
已完结
Effect of Induction Therapy With Olamkicept vs Placebo on Clinical Response in Patients With Active Ulcerative Colitis
1小时前
已完结
Real World Clinical Effectiveness and Safety of Ozanimod in the Treatment of Ulcerative Colitis: 1-Year Follow-Up from a Tertiary Center
2小时前
已完结
Prevention and interception trials in inflammatory bowel disease: an international taskforce assessment on clinical trial design
2个月前
已完结
Early liver transplantation for severe alcohol-related hepatitis not responding to medical treatment: a prospective controlled study
2个月前
已完结
Fibrosis in Ulcerative Colitis
2个月前
已完结
Investigating Zinc’s role in Mitigating Blood Lead Levels’ Toxicity on Gut Microbiota Diversity: NHANES 2007-2010
2个月前
已完结
Revisiting fibrosis in inflammatory bowel disease: the gut thickens
4个月前
已完结
Navigating the complexities of drug development for inflammatory bowel disease
4个月前
已完结
皖公网安备34019202002308
